Eplerenone improves kidney function and cardiac performance in obese male mice
Diabetic Medicine · 2026
DOI: 10.1111/dme.70154 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetic Medicine, 2026. Verfasst von Ayman K Banah und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Diabetes, Endocrinology, and Reproductive Biology, School of Medicine, University of Dundee, Dundee, Scotland, UK. Hauptthemen laut MEDLINE: Eplerenone, Obesity, Mineralocorticoid Receptor Antagonists, Kidney. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Kingdom of Saudi Arabia, Ministry of Education, Umm Al-Qura University, China Scholarship Council, British Heart Foundation.
Abstract (Originalsprache)
Aims
Renin‐angiotensin‐aldosterone system (RAAS) activation mediates obesity‐associated cardiorenal dysfunction. Due to an incomplete understanding of the molecular mechanisms, the clinical use of RAAS antagonism in obesity‐associated cardiometabolic complications remains uncertain. The present study investigated the effects and associated molecular mechanisms of eplerenone, a selective mineralocorticoid receptor antagonist, in the heart and kidney of obesity.
Methods
Male C57BL/6 mice were fed a high‐fat diet (HFD) for 12 weeks before receiving either vehicle or eplerenone treatments for 30 days while maintained on HFD. Cardiac function was measured by pressure–volume (PV) loop analyses. Renal function was assessed by renal morphology and serum creatinine concentrations. Chow‐fed mice were used as lean controls.
Results
HFD feeding impaired cardiac and renal function in mice, evidenced by elevated blood pressures, stroke work, Tau, glomerular hypertrophy and tubular injury. Eplerenone treatment caused weight loss, which was attributed to a loss in fat mass. Moreover, eplerenone treatment ameliorated both HFD‐induced cardiac and renal dysfunction, including a decrease in stroke volume, cardiac output and stroke work; an increase in ejection fraction; and a decrease in glomerular hypertrophy, tubular injury, renal fibrosis and serum creatinine concentrations. Mechanistically, eplerenone decreased CD44 but increased RHAMM and TGF‐β expression in the heart. In contrast, eplerenone caused a decrease in the hyaluronan‐CD44/RHAMM pathway, TGF‐β, IL‐6 and phosphorylation of Akt and JNK in the kidney.
Conclusion
Eplerenone treatment improved kidney function and cardiac performance in obese male mice. The potential link between the mineralocorticoid receptor and the hyaluronan‐CD44/RHAMM pathway is novel and has not been previously reported.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Diabetes, Endocrinology, and Reproductive Biology, School of Medicine, University of Dundee, Dundee, Scotland, UK.
- Nursing Sciences and Research, College of Nursing, Umm Al-Qura University, Makkah, Saudi Arabia.
- Precision Molecular Medicine Center, Jilin Province People's Hospital, Changchun, Jilin, China.
- Division of Cardiovascular Research, School of Medicine, University of Dundee, Dundee, Scotland, UK.
ORCID-Profile: Ayman K Banah, Bingxue Qi, Li Kang
Förderung
- Kingdom of Saudi Arabia, Ministry of Education, Umm Al-Qura University
- China Scholarship Council
- British Heart Foundation
- Diabetes UK
Zitieren
APA
Banah, A. K., Qi, B., Koh, R., Lawlor, A., Wang, T., Musale, V., Mains, J., Murdoch, C. E., & Kang, L. (2026). Eplerenone improves kidney function and cardiac performance in obese male mice. Diabetic Medicine. https://doi.org/10.1111/dme.70154
Vancouver
Banah AK, Qi B, Koh R, Lawlor A, Wang T, Musale V, et al. Eplerenone improves kidney function and cardiac performance in obese male mice. Diabetic Medicine. 2026. doi:10.1111/dme.70154
BibTeX
@article{Banah2026,
author = {Banah, Ayman K and Qi, Bingxue and Koh, Ryan and Lawlor, Alexander and Wang, Tianzhen and Musale, Vishal and Mains, Joanne and Murdoch, Colin E and Kang, Li},
title = {Eplerenone improves kidney function and cardiac performance in obese male mice},
journal = {Diabetic Medicine},
year = {2026},
doi = {10.1111/dme.70154}
}
EUVIMED